Table 4.

Results of Subsequent SARS-CoV-2 PCR or Antigen Tests Within 28 Days After Admission Date

	7–14-Day SARS-CoV-2-Positive Test Patients, No. (%)	14–21-Day SARS-CoV-2-Positive Test Patients, No. (%)	21–28-Day SARS-CoV-2-Positive Test Patients, No. (%)	7–28-Day SARS-CoV-2-Positive Test Patients, No. (%)
Group 0 (no ondansetron)	250/307 (81.4)	123/167 (73.7)	54/92 (58.8)	427/566 (75.4)
Group 1 (0–8 mg ondansetron/first 48 h)	18/21 (86)	9/14 (64)	3/4 (75)	30/39 (76)
Group 2 (≥8 mg ondansetron/first 48 h)	11/15 (73)	4/8 (50)	0/5 (0)	15/28 (54)

Patients who received ondansetron in the first 48 hours postadmission were less likely to have positive SARS-CoV-2 test results in the subsequent 4 weeks.

Abbreviations: PCR, polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.